[go: up one dir, main page]

WO2011093809A3 - Composition pharmaceutique en poudre sèche comprenant du tiotropium et du ciclésonide - Google Patents

Composition pharmaceutique en poudre sèche comprenant du tiotropium et du ciclésonide Download PDF

Info

Publication number
WO2011093809A3
WO2011093809A3 PCT/TR2011/000011 TR2011000011W WO2011093809A3 WO 2011093809 A3 WO2011093809 A3 WO 2011093809A3 TR 2011000011 W TR2011000011 W TR 2011000011W WO 2011093809 A3 WO2011093809 A3 WO 2011093809A3
Authority
WO
WIPO (PCT)
Prior art keywords
ciclesonide
tiotropium
dry powder
pharmaceutical composition
powder pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2011/000011
Other languages
English (en)
Other versions
WO2011093809A2 (fr
Inventor
Mahmut Bilgic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TR2010/00620A external-priority patent/TR201000620A2/xx
Priority claimed from TR2010/00729A external-priority patent/TR201000729A2/xx
Application filed by Individual filed Critical Individual
Publication of WO2011093809A2 publication Critical patent/WO2011093809A2/fr
Publication of WO2011093809A3 publication Critical patent/WO2011093809A3/fr
Priority to US13/531,972 priority Critical patent/US8834931B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques sous forme de poudre sèche comprenant du tiotropium et du ciclésonide et/ou leurs dérivés pharmaceutiquement acceptables utilisés comme principes actifs. Elle concerne également des formes en capsules ou plaquettes alvéolaires contenant ces compositions pharmaceutiques destinées à être utilisées dans le traitement de maladies des voies respiratoires.
PCT/TR2011/000011 2009-12-25 2011-01-28 Composition pharmaceutique en poudre sèche comprenant du tiotropium et du ciclésonide Ceased WO2011093809A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/531,972 US8834931B2 (en) 2009-12-25 2012-06-25 Dry powder formulation containing tiotropium for inhalation

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
TR2010/00620 2010-01-28
TR2010/00620A TR201000620A2 (tr) 2010-01-28 2010-01-28 Tiotropium ve siklesonid içeren kuru toz formundaki farmasötik kompozisyon.
TR2010/00729 2010-02-02
TR2010/00729A TR201000729A2 (tr) 2010-02-02 2010-02-02 Tiotropyum ve siklesonid içeren kuru toz formundaki farmasötik kompozisyon

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000012 Continuation-In-Part WO2011093810A2 (fr) 2009-12-25 2011-01-28 Composition pharmaceutique de poudre sèche comprenant du tiotropium et de la mométasone

Related Child Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2010/000251 Continuation-In-Part WO2011078824A1 (fr) 2009-12-25 2010-12-20 Formulation de poudre sèche contenant tiotropium et destinée à l'inhalation

Publications (2)

Publication Number Publication Date
WO2011093809A2 WO2011093809A2 (fr) 2011-08-04
WO2011093809A3 true WO2011093809A3 (fr) 2012-02-23

Family

ID=43928937

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000011 Ceased WO2011093809A2 (fr) 2009-12-25 2011-01-28 Composition pharmaceutique en poudre sèche comprenant du tiotropium et du ciclésonide

Country Status (1)

Country Link
WO (1) WO2011093809A2 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004019985A1 (fr) * 2002-08-29 2004-03-11 Cipla Ltd Produits et compositions pharmaceutiques comprenant des agents anticholinergiques specifiques, des agonistes beta-2 et des corticosteroides
US20040266869A1 (en) * 2000-12-15 2004-12-30 Montague Christopher John Novel medicament compositions based on anticholinesterase drugs and on ciclesonides
WO2008102128A2 (fr) * 2007-02-19 2008-08-28 Cipla Limited Combinaisons pharmaceutiques
US20090188497A1 (en) * 2003-12-03 2009-07-30 Boehringer Ingelheim International Gmbh Medical product containing tiotropium
WO2011078818A1 (fr) * 2009-12-25 2011-06-30 Bilgic Mahmut Combinaison de poudre sèche constituée de tiotropium, d'un corticostéroïde et d'un dérivé d'acide cromoglicique

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5482834A (en) 1982-05-17 1996-01-09 Hahnemann University Evaluation of nucleic acids in a biological sample hybridization in a solution of chaotrophic salt solubilized cells
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
TR200803523A1 (tr) 2008-05-16 2009-12-21 Bi̇lgi̇ç Mahmut Şerit ambalaj içeren düzenek
TR200803522A1 (tr) 2008-05-16 2009-12-21 Bi̇lgi̇ç Mahmut Kolay kullanımlı inhalasyon cihazı.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040266869A1 (en) * 2000-12-15 2004-12-30 Montague Christopher John Novel medicament compositions based on anticholinesterase drugs and on ciclesonides
WO2004019985A1 (fr) * 2002-08-29 2004-03-11 Cipla Ltd Produits et compositions pharmaceutiques comprenant des agents anticholinergiques specifiques, des agonistes beta-2 et des corticosteroides
US20090188497A1 (en) * 2003-12-03 2009-07-30 Boehringer Ingelheim International Gmbh Medical product containing tiotropium
WO2008102128A2 (fr) * 2007-02-19 2008-08-28 Cipla Limited Combinaisons pharmaceutiques
WO2011078818A1 (fr) * 2009-12-25 2011-06-30 Bilgic Mahmut Combinaison de poudre sèche constituée de tiotropium, d'un corticostéroïde et d'un dérivé d'acide cromoglicique

Also Published As

Publication number Publication date
WO2011093809A2 (fr) 2011-08-04

Similar Documents

Publication Publication Date Title
TN2012000566A1 (en) Dry powder formulation comprising an antimuscarinic drug
WO2012016889A3 (fr) Formulation de poudre sèche comprenant un inhibiteur de phosphodiestérase
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
IL223795A (en) History of Tetrahydro-Pyrido-Pyrimidine
IL216741A (en) History of imidazolidine-2-van 1,3-imaging modalities as 17-cyp inhibitors, pharmaceutical preparations containing them, and their use in the preparation of drugs for the treatment of diseases
IL213019A (en) Derivatives 1-Azo-3-Terroyl-Azoline, Pharmaceutical Preparations Containing and Using Them
WO2012021715A3 (fr) Formulations stables de linaclotide
WO2013183062A3 (fr) Formulations d'ibuprofène de goût agréable
WO2012098562A3 (fr) Compositions liquides pour administration par voie orale de sels de lanthane
TR201000680A2 (tr) Tiotropyum, formoterol ve budesonid içeren farmasötik bileşimler
IL222578A0 (en) Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same
TR201000733A2 (tr) Flutikazon, tiotropyum ve sodyum kromoglikat içeren farmasötik bileşimler.
WO2011093815A3 (fr) Compositions pharmaceutiques comprenant du formotérol et du mométasone
WO2011058245A8 (fr) Nouveaux derives de mannopyranoside ayant une activite anticancereuse
WO2011093818A3 (fr) Compositions pharmaceutiques comprenant du salmétérol et du fluticasone
IL213671A (en) Pharmaceutical preparations containing alglitazar, a process for their preparation and use for the preparation of medicines
WO2011101734A3 (fr) Poudre à goût masqué pour compositions en suspension de méthylprednisolone
IL225105A (en) Heterocyclic compounds, their process, their pharmaceutical preparations and their use in the preparation of drugs
WO2011139249A3 (fr) Composition pharmaceutique renfermant du cefdinir
WO2011093811A3 (fr) Préparations pharmaceutiques comprenant du formotérol et du fluticasone
WO2011093812A3 (fr) Formulation pharmaceutique comprenant du tiotropium et du budésonide sous forme de poudre sèche
WO2011093814A3 (fr) Compositions pharmaceutiques combinées comprenant du formotérol et du ciclésonide
WO2012030308A3 (fr) Formulation comprenant la cellobiose
WO2011093810A3 (fr) Composition pharmaceutique de poudre sèche comprenant du tiotropium et de la mométasone
WO2011108882A3 (fr) Composition pharmaceutique pour la prévention ou le traitement de l'ostéoarthrite contenant du rébamipide en tant que principe actif

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11707504

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11707504

Country of ref document: EP

Kind code of ref document: A2